ACT to Present at Terrapinn’s Stem Cells & Regenerative Medicine Congress in Boston

Matthew Vincent, Ph.D., Director of Business Development to Present Overview of Results from Company’s Three Ongoing Clinical Trials

ACT to Present at Terrapinn’s Stem Cells & Regenerative Medicine Congress in Boston

<0> Investors:CEOcast, Inc.,James Young, 212-732-4300orPress:ACT Corporate Communications,Bill Douglass, 646-450-3615orRusso PartnersMartina Schwarzkopf, Ph.D., 212-845-4292 </0>

Advanced Cell Technology, Inc. (“ACT”) (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that director of business development, Matthew Vincent, Ph.D., will be presenting at Terrapinn’s Stem Cells USA and Regenerative Medicine , September 20-21 in Boston.

Dr. Vincent’s presentation, “Advancing stem cell therapies to the clinic: ACT's three cellular therapy programs,” will be given on Thursday, Sept. 20 at 3:15 p.m. EDT. Dr. Vincent will discuss the meaning and significance of the results seen thus far in ACT’s three ongoing human clinical trials in the U.S. and E.U. for Dry Age-Related Macular Degeneration (Dry AMD) and Stargardt’s Macular Dystrophy (SMD).

Stargardt’s Macular Dystrophy (SMD) is one of the most common forms of macular degeneration in the world. SMD causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium or RPE cell layer.

Degenerative diseases of the retina are among the most common causes of untreatable blindness in the world. As many as thirty million people in the United States and Europe suffer from macular degeneration, which represents a $25-30 billion worldwide market that has yet to be effectively addressed. Approximately 10% of people ages 66 to 74 will have symptoms of macular degeneration, the vast majority the “dry” form of AMD – which is currently untreatable. The prevalence increases to 30% in patients 75 to 85 years of age.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit .